Navigation Links
Optimer Pharmaceuticals Reports Third Quarter 2009 Financial Results
Date:11/3/2009

ith Clostridium difficile infection (CDI) were presented at the 47th Annual Meeting of the Infectious Diseases Society of America in October 2009. Clinical investigator Mark Miller, M.D., presented data showing that patients treated with fidaxomicin had a faster time to resolution of diarrhea compared to those treated with vancomycin. Faster time to resolution of diarrhea may reduce the spread of CDI in healthcare facilities and improve patients' quality of life. Clinical investigator Kate Mullane, D.O., presented data showing that treatment with fidaxomicin compared to vancomycin in patients also receiving concomitant antibiotics resulted in higher clinical cure rates, lower recurrence rates and improved global cure rates.
  • Seven fidaxomicin-related abstracts from Optimer's North American Phase 3 study were presented at the 49th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in September 2009. The additional data presented highlight fidaxomicin's unique profile as a new antibiotic class with beneficial characteristics for treating CDI such as lower recurrence rates, reduced risk of vancomycin-resistant enteroccoci (VRE) acquisition, favorable pharmacokinetic profile, and a safety profile comparable to that of vancomycin.
  • The full data analysis from the second Phase 3 clinical study for Pruvel was presented at ICAAC in September 2009. Data presented by primary investigator Robert Steffen, M.D., showed that Pruvel shortened recovery time in adult travelers suffering from infectious diarrhea.
  • The United States Patent and Trademark Office recently issued a patent which covers the composition of matter of CEM-101/(OP-1068). CEM-101/(OP-1068) is a macrolide derivative originally developed by Optimer and licensed to Cempra Pharmaceuticals who recently completed a Phase 1 clinical trial for the treatment of respiratory infections.
  • About Optimer Pharmaceuticals

    Optimer Phar
    '/>"/>

    SOURCE Optimer Pharmaceuticals, Inc.
    Copyright©2009 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7

    Related biology technology :

    1. Optimer Pharmaceuticals to Present at September 2009 Investor Conferences
    2. Optimer Pharmaceuticals Announces Presentations of Additional Phase 3 Fidaxomicin and Prulifloxacin Data at Upcoming ICAAC Annual Meeting
    3. Optimer Pharmaceuticals Reports Second Quarter 2009 Financial Results
    4. Optimer Pharmaceuticals to Present at the Canaccord Adams 29th Annual Global Growth Conference
    5. Optimer Pharmaceuticals to Present at June 2009 Investor Conferences
    6. Optimer Pharmaceuticals Announces Lower Recurrence Rates for Fidaxomicin Versus Vancocin(R) in Subgroup Analyses from Its Phase 3 Study for the Treatment of CDI
    7. Optimer Pharmaceuticals Reports First Quarter 2009 Financial Results
    8. ISTA Pharmaceuticals Reports Third Quarter 2009 Financial Results
    9. Poniard Pharmaceuticals Reports Third Quarter 2009 Financial Results and Provides a Corporate Update
    10. OncoGenex Pharmaceuticals to Release Third Quarter 2009 Financial Results
    11. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Third Quarter 2009 Financial Results on November 5, 2009
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:12/24/2014)... 2014   BioLife Solutions , Inc. (NASDAQ: ... of proprietary clinical grade hypothermic storage and ... shipping products for cells and tissues  ("BioLife" or ... 2015 Annual Meeting of Stockholders on May 4, 2015 ... for the Annual Meeting represents a change of more ...
    (Date:12/24/2014)... (PRWEB) December 23, 2014 ... series is designed to introduce cutting edge ... users and partners of platform upgrades. This ... benefits; empowering users in their quest to ... tools. , According to SoundConnect’s Marketing Manager, ...
    (Date:12/24/2014)... Nashville, Tenn. (PRWEB) December 23, 2014 ... Hill was elected treasurer for the American Society ... to advancing knowledge and research in reproductive medicine. ... fills a seat on the executive board and will ... , Dr. Hill has actively supported ASRM since ...
    (Date:12/24/2014)... Texas , Dec. 23, 2014 ... company focused on gynecologic disease, announced today that ... Schuler , Birchview Fund LLC and several Vermillion ... of unregistered shares of Vermillion,s common stock and ... stock in a private placement.  ...
    Breaking Biology Technology:BioLife Solutions Sets Date for Annual Meeting of Stockholders 2SoundConnect Launches Leading Edge Business Communications Webinar Series 2SoundConnect Launches Leading Edge Business Communications Webinar Series 3Nashville Fertility Center Announces Dr. George A. Hill Selected to Serve as ASRM Treasurer for 2014-15 2Nashville Fertility Center Announces Dr. George A. Hill Selected to Serve as ASRM Treasurer for 2014-15 3Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 2Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 3Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 4Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 5
    ... for Chronic Pain IndicationsLA JOLLA, Calif., Feb. 11 ... ) today announced that oral administration of NGX426, ... well-tolerated in healthy male and female subjects when ... completion of this Phase I trial demonstrating the ...
    ... Mach One Corporation (Pink Sheets: MNCN), a global ... positive, long term benefit to the agricultural and consumer ... agreement to acquire Modular Process Constructors LLC.The purchase price ... with a conversion price of .50 per share will ...
    ... names that better reflect the unique properties and industry-leading characteristics of ... ... 2009 -- Zeus, Inc. announces new product name changes that signify ... unaltered in composition and processing. They remain the same quality ...
    Cached Biology Technology:First Multiple Dose Clinical Trial of TorreyPines Therapeutics' Oral Compound NGX426 Demonstrates Compound Is Safe and Well-Tolerated 2First Multiple Dose Clinical Trial of TorreyPines Therapeutics' Oral Compound NGX426 Demonstrates Compound Is Safe and Well-Tolerated 3First Multiple Dose Clinical Trial of TorreyPines Therapeutics' Oral Compound NGX426 Demonstrates Compound Is Safe and Well-Tolerated 4Mach One Executes Definitive Agreement to Acquire Biopharmaceutical Design & Engineering Firm 2Zeus Announces Product Name Changes 2
    (Date:12/19/2014)... and Markets ( http://www.researchandmarkets.com/research/86ncd6/micro_market ) has announced ... America Perimeter Security Systems Market" report to their ... The North American perimeter security market is estimated ... to 2019. Although the U.S. market holds a larger ... is expected to grow at a higher CAGR of ...
    (Date:12/17/2014)... , Dec. 15, 2014  HITLAB SM ... Practices (GCP) audit to confirm its adherence to ... This accomplishment enables HITLAB to conduct regulated smart ... highest principles for patient safety and research quality. ... healthcare access, quality, and delivery with innovative technology," ...
    (Date:12/11/2014)... --Research and Markets , ... ) has announced the addition of the ... to their offering. One major ... technology. With continuous advances in technology, it is ... standard that meets the needs and expectations of ...
    Breaking Biology News(10 mins):Micro Market Monitor: North America Perimeter Security Systems Market (Intrusion Detection Sensor, Video Surveillance, Communication/Alarm and Notification, Access Control System) 2Micro Market Monitor: North America Perimeter Security Systems Market (Intrusion Detection Sensor, Video Surveillance, Communication/Alarm and Notification, Access Control System) 3HITLAB Completes GCP Audit for FDA Smart Device & App Compliance 2Biometrics Market in the APAC Region 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2
    ... Center may have a new way to stop and even ... a third of all adults, some of them repeatedly. ... able to sense the presence of E. coli bacteria hiding ... process that then kicks them out. Knowing how the ...
    ... two different scents simultaneously, the brain processes them separately ... finding by researchers at Rice University in Houston is ... system. The study was published online today by the ... the Sept. 29 print edition. "Our discovery opens ...
    ... DURHAM, N.C. A new method for attaching ... to improve protein drugs significantly. Bioengineers at Duke ... animal model that the newly created protein-polymer combinations, known ... unprotected protein. The scientists say they are encouraged ...
    Cached Biology News:Nostrils alternate to process competing odors 2Novel polymer could improve protein-based drugs 2Novel polymer could improve protein-based drugs 3
    Anti-Src-Like Adaptor Protein-2 AVOID FREEZE/THAW CYCLES. Recognizes the ~25 and ~28 kDa forms SLAP-2....
    ... media for spontaneous ligand immobilization can be coupled ... antigen, or receptor to create an affinity matrix ... couple ligands via primary amines. Affi-Gel 10 gel ... 6.5 to 11; Affi-Gel 15 gel couples acidic ...
    pH-dependent fluorescence; Maximum intensity observed in basic solutions....
    Anti-Chicken IgY, (IgG) F(ab')2 Fragment Specific....
    Biology Products: